LONDON (ShareCast) - (Sharecast News) - US vaccine development company Novavax has agreed to supply the UK government with 60m doses of its Covid-19 vaccine, NVX-CoV2373, as early as the first quarter of 2021.
As part of the agreement, the UK will fund a Phase 3 clinical trial to assess the efficacy of the vaccine on the population.

The trial will be a randomised, double-blind, placebo-controlled efficacy study in approximately 9,000 adults aged 18 to 85 in the UK. It is expected to begin in the third quarter of this year and will assess the ability of the vaccine to protect against symptomatic Covid-19 disease as well as evaluate antibody and T-cell responses.

President and chief executive officer Stanley C. Erck said: "Our Phase 3 clinical trial in the UK will be a critical component to assess the efficacy of NVX-CoV2373, which in a Phase 1 trial has already demonstrated to be generally well-tolerated and to elicit robust antibody responses.

"We are also delighted to expand our collaboration with FUJIFILM Diosynth Biotechnologies to manufacture our antigen at its UK site."

Kate Bingham, chair of the UK government's Vaccines Taskforce, said: "We believe that Novavax has a highly innovative vaccine that could be the first in its class of protein-based vaccine options."

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE